Literature DB >> 24237125

Small-molecule inhibitors of IκB kinase (IKK) and IKK-related kinases.

Sabin Llona-Minguez1, Jessica Baiget, Simon P Mackay.   

Abstract

The transcription factors NF-κB and IFN control important signaling cascades and mediate the expression of a number of important pro-inflammatory cytokines, adhesion molecules, growth factors and anti-apoptotic survival proteins. IκB kinase (IKK) and IKK-related kinases (IKKε and TBK1) are key regulators of these biological pathways and, as such, modulators of these enzymes may be useful in the treatment of inflammatory diseases and cancer. We have reviewed the most recent IKK patent literature (2008-2012), added publications of interest overlooked in previous patent reviews and identified all the players involved in small-molecule inhibitors of the IKKs. This will provide the reader with a decisive summary of the IKK arena, a field that has reached maturity over a decade of research.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24237125     DOI: 10.4155/ppa.13.31

Source DB:  PubMed          Journal:  Pharm Pat Anal        ISSN: 2046-8954


  17 in total

1.  A naturally derived small molecule NDSM253 inhibits IKK1 to suppress inflammation response and promote bone healing after fracture.

Authors:  Liqi Shen; Yun Xiao; Hui Xie; Hongbin Zhao; Tao Luo; Lin Liu; Xuekun Pan
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

Review 2.  Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.

Authors:  Kyu Sic You; Yong Weon Yi; Jeonghee Cho; Jeong-Soo Park; Yeon-Sun Seong
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18

3.  Mutation of cysteine 46 in IKK-beta increases inflammatory responses.

Authors:  Ting Li; Vincent Kam Wai Wong; Zhi Hong Jiang; Shui Ping Jiang; Yan Liu; Ting Yu Wang; Xiao Jun Yao; Xiao Hui Su; Feng Gen Yan; Juan Liu; Elaine Lai-Han Leung; Xiao Qin Yi; Yuen Fan Wong; Hua Zhou; Liang Liu
Journal:  Oncotarget       Date:  2015-10-13

4.  Apigenin blocks IKKα activation and suppresses prostate cancer progression.

Authors:  Sanjeev Shukla; Rajnee Kanwal; Eswar Shankar; Manish Datt; Mark R Chance; Pingfu Fu; Gregory T MacLennan; Sanjay Gupta
Journal:  Oncotarget       Date:  2015-10-13

5.  Inhibitory Kappa B Kinase α (IKKα) Inhibitors That Recapitulate Their Selectivity in Cells against Isoform-Related Biomarkers.

Authors:  Nahoum G Anthony; Jessica Baiget; Giacomo Berretta; Marie Boyd; David Breen; Joanne Edwards; Carly Gamble; Alexander I Gray; Alan L Harvey; Sophia Hatziieremia; Ka Ho Ho; Judith K Huggan; Stuart Lang; Sabin Llona-Minguez; Jia Lin Luo; Kathryn McIntosh; Andrew Paul; Robin J Plevin; Murray N Robertson; Rebecca Scott; Colin J Suckling; Oliver B Sutcliffe; Louise C Young; Simon P Mackay
Journal:  J Med Chem       Date:  2017-08-15       Impact factor: 7.446

Review 6.  Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.

Authors:  Federica Begalli; Jason Bennett; Daria Capece; Daniela Verzella; Daniel D'Andrea; Laura Tornatore; Guido Franzoso
Journal:  Biomedicines       Date:  2017-08-22

7.  Stereoselective synthesis of carbocyclic analogues of the nucleoside Q precursor (PreQ0).

Authors:  Sabin Llona-Minguez; Simon P Mackay
Journal:  Beilstein J Org Chem       Date:  2014-06-11       Impact factor: 2.883

8.  Paeonol protects endotoxin-induced acute kidney injury: potential mechanism of inhibiting TLR4-NF-κB signal pathway.

Authors:  Hua-Ying Fan; Dong Qi; Chen Yu; Feng Zhao; Tao Liu; Zuo-Kai Zhang; Ming-Yan Yang; Lei-Ming Zhang; Da-Quan Chen; Yuan Du
Journal:  Oncotarget       Date:  2016-06-28

Review 9.  Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors.

Authors:  Jack A Prescott; Simon J Cook
Journal:  Cells       Date:  2018-08-23       Impact factor: 6.600

10.  CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-κB activation.

Authors:  Le-Meng Zhang; Jing-Jing Zhou; Chun-Lei Luo
Journal:  Arthritis Res Ther       Date:  2018-10-03       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.